ดร. เภสัชกรหญิง นันท์นภัส แสงเฟื่อง

2025

• Sangfuang N, McCoubrey LE, Awad A, Marzorati M, Ghyselinck J, Verstrepen L, Munck J, Medts J, Gaisford S, Basit AW. (2025). Effects of senotherapeutics on gut microbiome dysbiosis and intestinal inflammation in Crohn’s disease: a pilot study. Transl. Res. 278, 36-47. doi:10.1016/j.trsl.2025.02.004.
• Sangfuang N, Xie Y, McCoubrey LE, Taub M, Favaron A, Mai Y, Gaisford S, Basit AW. (2025). Investigating the bidirectional interactions between senotherapeutic agents and human gut microbiota. Eur J Pharm Sci. Jun 1;209:107098. doi:10.1016/j.ejps.2025.107098. Epub 2025 Apr 9. PMID: 40216167.

2024

• McCoubrey LE, Seegobin N, Sangfuang N, Moens F, Duyvejonck H, Declerck E, Dierick A, Marzorati M, Basit AW. (2024). The colon targeting efficacies of mesalazine medications and their impacts on the gut microbiome. J Control Release. May;369:630-641. doi: 10.1016/j.jconrel.2024.04.016. Epub 2024 Apr 11. PMID: 38599548.
• McCoubrey LE, Shen C, Mwasambu S, Favaron A, Sangfuang N, Thomaidou S, Orlu M, Globisch D, Basit AW. (2024). Characterising and preventing the gut microbiota's inactivation of trifluridine, a colorectal cancer drug. Eur J Pharm Sci. Dec 1;203:106922. doi: 10.1016/j.ejps.2024.106922. Epub 2024 Oct 3. PMID: 39368784.

2023

• Wang F, Sangfuang N, McCoubrey LE, Yadav V, Elbadawi M, Orlu M, Gaisford S, Basit AW. (2023). Advancing oral delivery of biologics: Machine learning predicts peptide stability in the gastrointestinal tract. Int J Pharm. Mar 5;634:122643. doi: 10.1016/j.ijpharm.2023.122643. Epub 2023 Jan 25. PMID: 36709014.